Ammonia: A Dangerous Waste Product
Ammonia is a natural byproduct of protein metabolism that must be efficiently removed from the body to prevent toxicity. When ammonia removal is disrupted, ammonia accumulates to dangerous levels in the blood, leading to hyperammonemia. Elevated ammonia levels can cause severe neurological symptoms, including confusion, seizures, coma, and potentially death, making effective ammonia management critical for patient survival and quality of life.
Two conditions where ammonia toxicity drives significant disease burden are urea cycle disorders and hepatic encephalopathy.
Urea Cycle Disorders
Urea cycle disorders (UCDs) are inherited genetic conditions that affect the body’s ability to remove toxic ammonia from the blood. The urea cycle operates in the liver and converts ammonia into urea, which can be safely eliminated. When one of the enzymes or transporters in this pathway is deficient or missing, ammonia accumulates to dangerous levels. There are as many as ~6,500 patients in the U.S. living with UCD today and approximately ~8,000 patients in the EU.
Many UCD patients require strict low-protein diets in combination with nitrogen scavengers. These medications can cause unpleasant side effects, including poor palatability, body odor, and gastrointestinal issues. Some formulations require dosing as many as 40 tablets per day, creating a significant treatment burden. Despite these challenges, strict adherence to these regimens is necessary to reduce the risk of hyperammonemic crises (HACs), a persistent and dangerous threat that can result in severe and permanent neurological symptoms, coma, and death.
Hepatic Encephalopathy
Our Ammonia Lowering Approach: KRRO-121
KRRO-121 is a GalNAc-conjugated RNA-editing oligonucleotide for the potential treatment of hyperammonemia in patients with UCDs of any mutational background as well as patients with HE. Utilizing Korro’s proprietary OPERA® platform, KRRO-121 is designed to generate a stabilized, de novo glutamine synthetase (GS) protein, a critical enzyme involved in ammonia clearance. This synthetic rescue approach is designed to augment ammonia clearance in hyperammonemia-driven diseases such as UCDs and HE.
In patients with UCDs, this added clearance capacity has the potential to increase metabolic reserve, helping buffer ammonia excursions caused by dietary protein, acute illness or infection, and metabolic stress. The preclinical data for KRRO-121 show the potential for it to be a pan-UCD treatment that may blunt ammonia excursions and enable increased protein intake. KRRO-121 also has the potential to enhance ammonia control in HE patients, which may reduce the risk of recurrent HE episodes.
KRRO-121 may offer infrequent subcutaneous dosing, which, if confirmed in clinical studies, could offer significant improvement over current treatments that require multiple daily doses. KRRO-121 has the potential to be a differentiated, first-in-class, disease-modifying therapy for both UCD and HE.